Blue Sky Health Sector Stock Volatility Report

Notable Movers & Volatility

Dispersion was extreme. TEM led at +40.82% ($57.72 → $81.28), closing at 96.10% of its range with a +20.94% period return — and it was also the biggest volatility surprise at 4.94x realized versus implied, meaning options markets badly underpriced the move. EBS (+35.58%) and MRNA (+24.22%) followed, both finishing near their highs (98.38% and 87.49%). MRNA is notable for realized vol (80.52%) exceeding implied (71.33%) outright.

At the other end, KPTI fell -42.06% ($2.14 → $1.24), though it closed at 62.22% of its range with only a -3.74% period return — a violent round trip rather than a clean downtrend. CDXS (-25.95%), DBVT (-22.70%), SYK (-19.91%) and QURE (-19.41%) round out the decliners, and SYK's 2.84x and AMGN's 2.05x ratios show large-cap names also outrunning their implied vol.

Conversely, implied vol looked expensive in the highest-IV small caps: CDXS (256.25% IV, 0.39x), DBVT (0.66x), QURE (0.71x) and ADMA (0.70x) all realized far less than priced. XLV's 0.60x and 14.34% realized vol confirm the index absorbed far less movement than its components. Weak closes clustered in CVS (1.50%), UNH (5.14%) and BMY (5.42%).

Broader Market Context

Differential behavior within the sector. The spread from TEM (+40.82%) to KPTI (-42.06%) is roughly 83 percentage points across a single sector — a range far wider than any sector-level index move could produce, and XLV's modest -6.09% change with just 14.34% realized volatility makes that plain. Sub-groups clearly pulled apart:

• Biotech/vaccines and health-tech carried the upside: TEM, EBS, MRNA, BNTX (-18.44%) — high-beta names with realized vol between 44% and 80%.
• Managed care split sharply: CNC (+12.65%), ELV (+9.31%) and CI (+6.83%) gained, while UNH (-8.09%), HUM (-9.42%) and CVS (-8.46%) fell, with UNH and CVS closing near range lows. That internal divergence is more consistent with company-specific positioning than a single sector-wide driver.
• Large-cap pharma and devices were broadly heavy: LLY (-11.97%), ABT (-14.04%), AMGN (-16.23%), SYK (-19.91%), MRK (-9.30%), JNJ (-7.25%).

Rotation versus idiosyncratic moves. This does not look like a clean defensive rotation into healthcare; defensives (JNJ, MRK, ABBV, BMY) were the weak cohort, while the most speculative names produced the largest gains. That pattern is more consistent with risk-on appetite for high-beta, catalyst-driven names alongside de-rating in mega-cap pharma and devices — with AMGN (2.05x), SYK (2.84x) and ABT (2.08x) realizing well above implied, suggesting genuinely stock-level repricing rather than a smooth index drift.

Plausible current drivers. Without asserting specific events, the shape of this data is consistent with several recurring sector forces:

• Policy and reimbursement uncertainty — drug pricing, Medicare/Medicaid rate and utilization debates — which typically hit managed care and large-cap pharma hardest and could plausibly relate to the UNH/HUM/CVS weakness and the CNC/ELV/CI divergence.
• Binary clinical and regulatory catalysts in small-cap biotech, the usual explanation for moves like TEM, EBS, KPTI, DBVT and CDXS, where implied vol was often extremely high (CDXS 256%, KPTI 164%, DBVT 141%) yet realized outcomes varied widely.
• Rate and growth expectations, which affect long-duration biotech valuations disproportionately.
• M&A speculation, which tends to produce exactly the sharp single-name upside and elevated realized/implied ratios visible at the top of this list.